Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Cuts One in Four Jobs as it Struggles to Become Profitable

NEW YORK, Jan. 30 - In an effort to become profitable, Cellomics has laid off 50 employees, or one in four workers, and postponed one of its major research drives, the company said on Tuesday.

 

Cellomics was planning to launch a more ambitious second business-development phase in which it would develop collaborative deals to apply its systems in toxicology, target identification and validation, said President and CEO D. Lansing Taylor. As part of that effort, the company staffed up new departments and filed papers for an IPO in the spring of 2000.

 

But given current market conditions, the project has been sidelined for now, Taylor conceded.

 

"Some of [our plans] we're just not going to pursue aggressively," he said. "The market is rewarding profitability, not upside value. So we're focused on making the platform business--the Phase I model--profitable."

 

Cellomics hopes to touch black by the end of 2002 or the beginning of 2003, he added.

 

The new departments have been cut back to skeleton staffing, said Taylor. The layoffs represented about 25 percent of Cellomics' workforce.

 

Another project that has been put on the back burner is the company's efforts to develop cell chip technology for patterning and microplates. "Since there's not a market today for miniaturization, we're delaying product development," said Taylor.

 

He also said that the company was prepared to go public as soon as market conditions became favorable again. "When there is a window, we are prepared to go through it."

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.